Product Description
anti-CD30 CAR T cells for CD30 positive Hodgkin's lymphoma and Non-Hodgkin's lymphoma (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02259556)
Mechanisms of Action: CAR-T
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shanghai First Song Biotechnology Co., LTD
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Relapsed/Refractory Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CD20/CD30-CN-A1 | P1 |
Recruiting |
Relapsed/Refractory Lymphoma |
2025-09-01 |